한글목차

세벨리파제 알파의 주요 성장 촉진요인

1. 시장 점유율 확대 및 신규 환자 수 증가

• 세베리파제 알파는 리소좀 산성 리파제 결핍증(LAL-D) 치료 분야에서 질환의 근본 원인을 표적으로 하는 유일한 승인된 효소대체요법으로서 선도적인 입지를 유지하고 있습니다.
• 질병에 대한 인식 개선, 유전자 검사의 보급, 조기 진단의 발전으로 특히 소아 및 영아 발병 환자군에서 신규 치료 시작 환자 수가 증가하고 있습니다.
• 전 세계 지속적인 의사 교육, 신생아 선별검사 시범사업, 희귀질환 의뢰 네트워크가 보급을 안정적으로 지원하고 있습니다.

2. 중요한 적응증으로 확대

• 1. 리소좀 산성 리파아제 결핍증(LAL-D) : 세베리파제 알파는 간 및 심혈관계 합병증을 유발하는 효소 결핍증에 대응하기 위해 영아기 발병형 및 후기 발병형 LAL-D에 대해 모두 승인되었습니다.
• 소아 및 성인 사용: 진행성 간질환 및 이상지질혈증을 앓고 있는 청소년 및 성인을 포함한 전 연령층에서 채택이 증가하고 있습니다.
• 중증 영아형: 월만병에서 세베리파제 알파는 기존 치료 결과에 비해 생존율을 크게 향상시켜 높은 채택률을 보이고 있습니다.
• 바이오마커 및 레지스트리 확대: 진행 중인 자연경과 연구와 레지스트리 연구를 통해 진단 정확도를 높이고 조기 개입을 돕고 있습니다.

3. 지역적 확장

• 세베리파제 알파는 북미, 유럽, 아시아태평양, 라틴아메리카 및 중동 일부 지역에서 시판되고 있습니다.
• 아시아태평양과 중동은 유전자 스크리닝 증가와 희귀질환에 대한 인식이 높아지면서 성장 시장으로 부상하고 있습니다.
• Alexion(AstraZeneca Rare Disease)은 지역 유통 네트워크, 치료 센터, 상환 파트너십을 지속적으로 강화하고 있습니다.

4. 신규 적응증 승인

• 이번 규제 당국의 승인은 영아 발병형과 후기 발병형 LAL-D를 모두 대상으로 하고 있으며, 대상 환자군을 크게 확대했습니다.
• 보건당국은 세베리파제 알파를 LAL-D로 확진된 환자들의 1차 표준 치료제로 삼기 위해 임상 가이드라인을 지속적으로 업데이트하고 있습니다.
• 현재 진행 중인 소아 임상 연구를 통해 투여 및 장기 치료 전략이 더욱 정교해질 수 있습니다.

5. LAL-D의 강력한 수량 추이

• LAL-D는 만성적이고 생명을 위협하는 질환 특성으로 인해 치료 횟수가 지속되고 있으며, 유일한 상업적 촉진요인으로 남아있습니다.
• 조기 진단과 치료로 생존율, 간 기능, 지질 프로파일이 개선되어 의사들의 신뢰가 지속적으로 증가하고 있습니다.
• 리얼월드 레지스트리 데이터는 지속적인 임상적 효과와 장기적인 질병 안정화를 보여줍니다.

6. 경쟁 차별화 및 시장 동향

• LAL-D에 대한 최초이자 유일한 질환 특이적 효소대체요법이며, 직접적인 경쟁 제품은 존재하지 않습니다.
• 정맥주사 요법은 효소 결핍의 근본 원인을 다루기 때문에 지질 저하 요법이나 이식 요법과는 차별화됩니다.
• 초희귀질환 치료, 정밀진단, 신생아 선별검사 확대 등 광범위한 동향이 시장에 긍정적인 영향을 미치고 있습니다.
• 리얼월드 증거와 환자 등록 시스템에 대한 의존도가 높아짐에 따라 보험사와 정책 입안자의 신뢰가 강화되고 있습니다.

세벨리파제 알파의 최근 개발 현황

세베리파제 알파는 세계 접근성 확대, 장기 레지스트리 데이터, 소아 및 성인 LAL-D 환자군의 리얼월드 데이터에 초점을 맞추었습니다. 아스트라제네카 희귀질환 사업부는 대사성 질환 치료 포트폴리오에서 카누마의 핵심 치료제로서의 중요성을 지속적으로 강조하고 있으며, 새로운 데이터를 통해 간과 심혈관계에 대한 지속적인 효과를 확인했습니다. 신생아 선별검사 시범사업과 희귀질환 진단 경로 확대를 위한 노력으로 환자의 조기 발견과 치료 도입이 더욱 촉진되어 세벨리파제 알파의 LAL-D 치료 선도적 입지가 더욱 강화될 것으로 기대됩니다.

이 보고서는 세베리파제 알파의 주요 7개국(미국, 독일, 프랑스, 이탈리아, 스페인, 영국, 일본) 시장을 조사 분석했으며, 각국 시장 규모와 예측, 연구개발(R&D) 활동, 경쟁 구도 등의 정보를 전해드립니다.

목차

제1장 리포트의 개요

제2장 콜레스테롤 에스테르 축적증 및 볼만병 등의 승인된 적응증에서 세벨리파제 알파의 개요

제3장 세벨리파제 알파의 경쟁 상황(출시의 치료법)

제4장 경쟁 구도(후기 단계의 새로운 세벨리파제 알파 요법)

제5장 세벨리파제 알파 시장 평가

제6장 세벨리파제 알파 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

Key Factors Driving Sebelipase alfa Growth

1. Market Share Gains and New Patient Starts

• Sebelipase alfa continues to dominate the treatment landscape for lysosomal acid lipase deficiency (LAL-D) as the only approved enzyme replacement therapy targeting the root cause of the disease.
• Rising disease awareness, genetic testing, and earlier diagnosis are driving new patient starts, particularly in pediatric and infantile-onset populations.
• Ongoing physician education, newborn screening pilots, and rare-disease referral networks are supporting steady global adoption.

2. Expansion Across Key Indications

• Lysosomal Acid Lipase Deficiency (LAL-D): Sebelipase alfa is approved for both infantile-onset and later-onset LAL-D, addressing the enzyme deficiency responsible for hepatic and cardiovascular complications.
• Pediatric and Adult Use: Increasing uptake across all age groups, including adolescents and adults with progressive liver disease and dyslipidemia.
• Severe Infantile Form: Strong adoption in Wolman disease, where sebelipase alfa significantly improves survival compared with historical outcomes.
• Biomarker and Registry Expansion: Ongoing natural history and registry studies are refining diagnosis and supporting earlier intervention.

3. Geographic Expansion

• Sebelipase alfa is marketed across North America, Europe, Asia-Pacific, and parts of Latin America and the Middle East.
• Asia-Pacific and Middle East regions are emerging growth markets due to increasing genetic screening and rare-disease awareness.
• Alexion (AstraZeneca Rare Disease) continues to strengthen regional distribution networks, treatment centers, and reimbursement partnerships.

4. New Indication Approvals

• Regulatory approvals cover both infantile-onset and later-onset LAL-D, significantly broadening the eligible patient population.
• Health authorities continue to update clinical guidelines to position sebelipase alfa as first-line standard of care for confirmed LAL-D.
• Ongoing pediatric real-world studies may further refine dosing and long-term treatment strategies.

5. Strong LAL-D Volume Momentum

• LAL-D remains the sole commercial growth driver, with sustained treatment volumes due to the chronic, life-threatening nature of the disease.
• Early diagnosis and treatment are leading to improved survival, liver function, and lipid profiles, driving continued physician confidence.
• Real-world registry data show durable clinical benefits and long-term disease stabilization.

6. Competitive Differentiation and Market Trends

• First and only disease-specific enzyme replacement therapy for LAL-D, with no direct competitors.
• Intravenous therapy addresses the root enzymatic deficiency, differentiating it from lipid-lowering or transplant-based approaches.
• The market benefits from broader trends toward ultra-rare disease therapies, precision diagnostics, and newborn screening expansion.
• Growing reliance on real-world evidence and patient registries is reinforcing payer and policy-maker confidence.

Sebelipase alfa Recent Developments

Sebelipase alfa has centered on expanded global access, long-term registry data, and real-world evidence in pediatric and adult LAL-D populations. AstraZeneca Rare Disease has continued to highlight Kanuma as a cornerstone therapy in its metabolic portfolio, with new data confirming sustained liver and cardiovascular benefits. Efforts to expand newborn screening pilots and rare-disease diagnostic pathways are expected to further increase early patient identification and treatment uptake, reinforcing Sebelipase alfa's leadership in LAL-D.

"Sebelipase alfa Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of Sebelipase alfa for approved indication like Cholesterol ester storage disease and Wolman disease in the 7MM. A detailed picture of Sebelipase alfa's existing usage in anticipated entry and performance in approved indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the Sebelipase alfa for approved indications. The Sebelipase alfa market report provides insights about Sebelipase alfa's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Sebelipase alfa performance, future market assessments inclusive of the Sebelipase alfa market forecast analysis for approved indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Sebelipase alfa sales forecasts, along with factors driving its market.

Sebelipase alfa Drug Summary

Sebelipase alfa (Kanuma) is a recombinant human lysosomal acid lipase (LAL) enzyme replacement therapy approved for treating lysosomal acid lipase deficiency (LAL-D), a rare autosomal recessive lysosomal storage disorder caused by pathogenic variants in the LIPA gene that result in deficient or absent LAL enzyme activity, leading to lysosomal accumulation of cholesteryl esters and triglycerides in organs such as the liver, spleen, intestine, adrenals, and vasculature. The enzyme binds to cell surface receptors via mannose-6-phosphate glycans, undergoes receptor-mediated endocytosis primarily in hepatocytes and macrophages, and catalyzes the lysosomal hydrolysis of cholesteryl esters and triglycerides into free cholesterol, free fatty acids, and glycerol, thereby alleviating lipid engorgement, improving liver function (reduced ALT/AST), decreasing hepatomegaly and hepatic fat content, correcting dyslipidemia (lowered LDL-C and triglycerides, elevated HDL-C), enhancing growth and survival in infantile-onset Wolman disease, and mitigating cardiovascular and gastrointestinal complications in childhood/adult-onset cholesteryl ester storage disease. Administered via intravenous infusion every other week (1 mg/kg for pediatric/adult patients; 1-3 mg/kg weekly for infants with dose escalation), it is produced in the egg whites of genetically engineered chickens and requires premedication and monitoring for potential hypersensitivity or anaphylactic reactions in specialized treatment centers. The report provides Sebelipase alfa's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Sebelipase alfa Market Report

The report provides insights into:

• A comprehensive product overview including the Sebelipase alfa MoA, description, dosage and administration, research and development activities in approved indication like Cholesterol ester storage disease and Wolman disease.
• Elaborated details on Sebelipase alfa regulatory milestones and other development activities have been provided in Sebelipase alfa market report.
• The report also highlights Sebelipase alfa's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved indications across the United States, Europe, and Japan.
• The Sebelipase alfa market report also covers the patents information, generic entry and impact on cost cut.
• The Sebelipase alfa market report contains current and forecasted Sebelipase alfa sales for approved indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Sebelipase alfa market report also features the SWOT analysis with analyst views for Sebelipase alfa in approved indications.

Methodology:

The Sebelipase alfa market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Sebelipase alfa Analytical Perspective by DelveInsight

• In-depth Sebelipase alfa Market Assessment

This Sebelipase alfa sales market forecast report provides a detailed market assessment of Sebelipase alfa for approved indication like Cholesterol ester storage disease and Wolman disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Sebelipase alfa sales data uptil 2034.

• Sebelipase alfa Clinical Assessment

The Sebelipase alfa market report provides the clinical trials information of Sebelipase alfa for approved indications covering trial interventions, trial conditions, trial status, start and completion dates.

Sebelipase alfa Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Sebelipase alfa Market Potential & Revenue Forecast

• Projected market size for the Sebelipase alfa and its key indications
• Estimated Sebelipase alfa sales potential (Sebelipase alfa peak sales forecasts)
• Sebelipase alfa Pricing strategies and reimbursement landscape

Sebelipase alfa Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Sebelipase alfa Market positioning compared to existing treatments
• Sebelipase alfa Strengths & weaknesses relative to competitors

Sebelipase alfa Regulatory & Commercial Milestones

• Sebelipase alfa Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Sebelipase alfa Clinical Differentiation

• Sebelipase alfa Efficacy & safety advantages over existing drugs
• Sebelipase alfa Unique selling points

Sebelipase alfa Market Report Highlights

• In the coming years, the Sebelipase alfa market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Sebelipase alfa companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Sebelipase alfa's dominance.
• Other emerging products for Cholesterol ester storage disease and Wolman disease are expected to give tough market competition to Sebelipase alfa and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Sebelipase alfa in approved indications.
• Analyse Sebelipase alfa cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Sebelipase alfa sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Sebelipase alfa in approved indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of Sebelipase alfa? How strong is Sebelipase alfa's clinical and commercial performance?
• What is Sebelipase alfa's clinical trial status in each individual indications such as Cholesterol ester storage disease and Wolman disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Sebelipase alfa Manufacturers?
• What are the key designations that have been granted to Sebelipase alfa for approved indications? How are they going to impact Sebelipase alfa's penetration in various geographies?
• What is the current and forecasted Sebelipase alfa market scenario for approved indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Sebelipase alfa in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Sebelipase alfa for approved indications?
• Which are the late-stage emerging therapies under development for the treatment of approved indications?
• How cost-effective is Sebelipase alfa? What is the duration of therapy and what are the geographical variations in cost per patient?

Table of Contents

1. Report Introduction

2. Sebelipase alfa Overview in approved indications like Cholesterol ester storage disease and Wolman disease

• 2.1. Product Detail
• 2.2. Sebelipase alfa Clinical Development
  • 2.2.1. Sebelipase alfa Clinical studies
  • 2.2.2. Sebelipase alfa Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Sebelipase alfa Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Sebelipase alfa Therapies)

5. Sebelipase alfa Market Assessment

• 5.1. Sebelipase alfa Market Outlook in approved indications
• 5.2. 7MM Analysis
  • 5.2.1. Sebelipase alfa Market Size in the 7MM for approved indications
• 5.3. Country-wise Market Analysis
  • 5.3.1. Sebelipase alfa Market Size in the United States for approved indications
  • 5.3.2. Sebelipase alfa Market Size in Germany for approved indications
  • 5.3.3. Sebelipase alfa Market Size in France for approved indications
  • 5.3.4. Sebelipase alfa Market Size in Italy for approved indications
  • 5.3.5. Sebelipase alfa Market Size in Spain for approved indications
  • 5.3.6. Sebelipase alfa Market Size in the United Kingdom for approved indications
  • 5.3.7. Sebelipase alfa Market Size in Japan for approved indications

6. Sebelipase alfa SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options